@Article{Rejdak2012,
journal="Klinika Oczna / Acta Ophthalmologica Polonica",
issn="0023-2157",
volume="114",
number="4",
year="2012",
title="New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia",
abstract="Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of choroidal and retinal neovascularization. Anti-VEGF therapy changed the standard-of-care for ocular disease with neovascularisation. This article presents one promising new drug – VEGF Trap-Eye – and results of clinical trials evaluating its efficacy in the treatment of wet age-related macular degeneration, central retinal vain occlusion, diabetic macular edema and choroidal neovascularization secondary to pathologic myopia.",
author="Rejdak, Robert
and Szkaradek, Małgorzata
and Taslaq, Wesam
and Kałużny, Jakub
and Grieb, Paweł
and Jünemann, Anselm",
pages="308--310",
url="https://www.termedia.pl/New-drug-VEGF-Trap-Eye-Eylea-and-its-use-in-the-treatment-of-age-related-r-nmacular-degeneration-central-retinal-vein-occlusion-diabetic-macular-edema-r-nand-choroidal-neovascularization-secondary-to-,124,48571,1,1.html"
}